Welcome to our dedicated page for BBI news (Ticker: BBI), a resource for investors and traders seeking the latest updates and insights on BBI stock.
Brickell Biotech, Inc. (BBI) is a clinical-stage pharmaceutical company advancing innovative therapies for debilitating skin conditions, with its lead candidate sofpironium bromide targeting hyperhidrosis (excessive sweating). This news hub provides investors and industry observers with timely updates on BBI's clinical developments, strategic initiatives, and regulatory milestones.
Access authoritative information on key activities including clinical trial progress, financial announcements, and partnership developments. The curated news collection serves as a reliable resource for tracking BBI's progress in bringing differentiated dermatological treatments to market.
Stay informed about corporate strategies through verified press releases and objective reporting, including updates on shareholder value optimization and planned cash distributions pending approvals. Content reflects insights from leadership with proven success in commercializing landmark therapies.
Bookmark this page for consolidated access to BBI's latest announcements. Monitor developments from the team behind pharmaceutical innovations like Cialis® and Taltz® as they address unmet needs in dermatological care.
Fresh Tracks Therapeutics reported positive topline results from the Phase 1 study of FRTX-02, a potential first-in-class oral treatment for atopic dermatitis and autoimmune diseases. The company raised $6.6 million through an at-the-market program in March 2023, enhancing liquidity. For 2022, revenue increased to $6.9 million from $0.4 million in 2021, driven by contract revenue from an asset sale agreement with Botanix. R&D expenses decreased significantly to $14.0 million from $28.2 million, supporting a path toward strategic options aimed at maximizing shareholder value. The net loss shrank to $21.1 million in 2022 from $39.5 million in 2021.
Fresh Tracks Therapeutics announced positive topline results from its Phase 1 clinical trial for FRTX-02, a potential first-in-class treatment for autoimmune diseases. The trial demonstrated that FRTX-02 was generally safe and well-tolerated, supporting its potential as a once-daily oral therapy. Key findings included dose-proportional pharmacokinetics and significant reductions in disease-relevant cytokines, indicating its efficacy in modulating immune responses. The company plans to explore strategic options to enhance shareholder value while advancing development of its innovative therapeutic pipeline.
Fresh Tracks Therapeutics has appointed Andrew Sklawer as the new CEO, effective February 1, 2023, succeeding Rob Brown, who is retiring after leading the company since 2019. Sklawer, a co-founder, will continue to advance the company’s innovative therapeutics targeting autoimmune and inflammatory diseases, with key milestones expected from the ongoing FRTX-02 clinical study.
Brown will remain on the Board of Directors and serve as a special advisor. Reginald Hardy, Chairman, emphasized Sklawer's instrumental role in shaping the company's strategic direction and enhancing shareholder value.
FAQ
What is the market cap of BBI (BBI)?
